{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:17:44Z","timestamp":1773497864144,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.3816\/clm.2006.s.005","type":"journal-article","created":{"date-parts":[[2008,9,12]],"date-time":"2008-09-12T01:03:13Z","timestamp":1221181393000},"page":"S24-S32","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S1","title":["New Directions in the Treatment of Mantle Cell Lymphoma: An Overview"],"prefix":"10.3816","volume":"7","author":[{"given":"Andre","family":"Goy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7suppl 6","key":"10.3816\/CLM.2006.s.005_bib1","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/annonc\/7.suppl_6.S35","article-title":"Mantle-cell lymphoma: classification and therapeutic implications","author":"Fisher","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib2","first-page":"49","article-title":"Management of mantle cell lymphoma","volume":"12","author":"Armitage","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"10.3816\/CLM.2006.s.005_bib3","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle cell lymphoma: a clinicopathologic study of 80 cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.3816\/CLM.2006.s.005_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/11.suppl_1.S123","article-title":"The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)","volume":"11","author":"Ghielmini","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib6","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib7","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus highdose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib8","doi-asserted-by":"crossref","first-page":"390a","DOI":"10.1182\/blood.V104.11.1388.1388","article-title":"Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: a Wisconsin Oncology Network study","volume":"104","author":"Kahl","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.1998.16.2.579","article-title":"Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas","volume":"16","author":"Decaudin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428190109097721","article-title":"Cyclophosphamide\/fludarabine (CF) is active in the treatment of mantle cell lymphoma","volume":"42","author":"Cohen","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2006.s.005_bib12","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/A:1008325212484","article-title":"Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse","volume":"10","author":"Rummel","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib14","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","article-title":"Reduced-dose cladribine (2- CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma","volume":"38","author":"Rummel","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2006.s.005_bib15","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/cncr.22196","article-title":"Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma","volume":"107","author":"Robak","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.s.005_bib16","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00001622-200403000-00004","article-title":"An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Jacobsen","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/sj.bmt.1703255","article-title":"Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?","volume":"28","author":"Sweetenham","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2006.s.005_bib19","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves eventfree survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2006.s.005_bib21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1083-8791(00)70030-9","article-title":"Autologous hematopoietic stem cell transplantation for mantle cell lymphoma","volume":"6","author":"Vose","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2006.s.005_bib22","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib23","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2006.s.005_bib24","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLM.2006.s.005_bib25","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.bmt.1703296","article-title":"Rituximab: enhancing stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Gianni","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2006.s.005_bib26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.seminoncol.2003.12.008","article-title":"Clearing minimal residual disease with rituximab consolidation therapy","volume":"31","author":"Brugger","year":"2004","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2003.12.002","article-title":"Integrating monoclonal antibodies into the management of mantle cell lymphoma","volume":"31","author":"Berinstein","year":"2004","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib29","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib30","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib31","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib32","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma","volume":"91","author":"de Guibert","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2006.s.005_bib33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/sonc.2002.30143","article-title":"Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma","volume":"29","author":"Mangel","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib35","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/sonc.2003.50057","article-title":"CD22 as a target of passive immunotherapy","volume":"30","author":"Cesano","year":"2003","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib37","doi-asserted-by":"crossref","first-page":"71a","DOI":"10.1182\/blood.V106.11.230.230","article-title":"Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL)","volume":"106","author":"Advani","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib38","doi-asserted-by":"crossref","first-page":"425a","DOI":"10.1182\/blood.V106.11.1473.1473","article-title":"Targeting CD20 and CD22 with rituximab in combination with CMC-544 results in improved anti-tumor activity against non-Hodgkin's lymphoma (NHL) pre-clinical models","volume":"106","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib39","doi-asserted-by":"crossref","first-page":"433a","DOI":"10.1182\/blood.V106.11.1504.1504","article-title":"A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma","volume":"106","author":"Advani","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib40","doi-asserted-by":"crossref","first-page":"146a","DOI":"10.1182\/blood.V106.11.489.489","article-title":"Results of a phase 2 trial of HGSETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in subjects with relapsed\/refractory non-Hodgkin's lymphoma (NHL)","volume":"106","author":"Younes","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib41","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma","volume":"11","author":"Neelapu","year":"2005","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2006.s.005_bib42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","article-title":"Principles and use of anti-CTLA4 antibody in human cancer immunotherapy","volume":"18","author":"Peggs","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"10.3816\/CLM.2006.s.005_bib43","doi-asserted-by":"crossref","first-page":"720a","DOI":"10.1182\/blood.V104.11.2632.2632","article-title":"A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)","volume":"104","author":"Oki","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib44","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1200\/jco.2006.24.18_suppl.7533","article-title":"Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL Network and the PLRG","volume":"24","author":"Weigert","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib45","first-page":"406a","article-title":"Tositumomab followed by CHOP in sequential therapy for mantle cell lymphoma","volume":"102","author":"Zelenetz","year":"2003","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.s.005_bib46","first-page":"422s","article-title":"Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1499)","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc1361","article-title":"The proteasome: a suitable antineoplastic target","volume":"4","author":"Adams","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CLM.2006.s.005_bib48","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2006.s.005_bib49","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib50","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib51","doi-asserted-by":"crossref","first-page":"175a","DOI":"10.1182\/blood.V104.11.608.608","article-title":"Phase II trial of bortezomib in mantle cell lymphoma","volume":"104","author":"Belch","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib52","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","article-title":"Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity","volume":"24","author":"Strauss","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib53","doi-asserted-by":"crossref","first-page":"575s","DOI":"10.1200\/jco.2005.23.16_suppl.6563","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CLM.2006.s.005_bib54","first-page":"425a","article-title":"Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): results of the PINNACLE study","volume":"24","author":"Goy","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib55","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Perez-Galan","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib56","first-page":"147a","article-title":"Phase I\/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results","volume":"104","author":"Leonard","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib57","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V104.11.1387.1387","article-title":"Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells","volume":"104","author":"Goy","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib58","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib59","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2006.s.005_bib60","doi-asserted-by":"crossref","first-page":"6631","DOI":"10.1200\/jco.2005.23.16_suppl.6631","article-title":"A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"23","author":"Feldman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib61","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib62","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O'Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2005.00546.x","article-title":"Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma","volume":"76","author":"Heider","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2006.s.005_bib64","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/jco.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib65","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10428190290016908","article-title":"Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma","volume":"43","author":"Lin","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2006.s.005_bib66","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-05-0831","article-title":"Chronic lymphocytic leukemia: a niche for flavopiridol?","volume":"11","author":"Brown","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2006.s.005_bib67","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","article-title":"The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","volume":"65","author":"Graff","year":"2005","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2006.s.005_bib68","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"10.3816\/CLM.2006.s.005_bib69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.28.11.1","article-title":"Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling","volume":"11","author":"Lam","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2006.s.005_bib70","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1158\/1078-0432.2.11.1","article-title":"From microarray to bedside: targeting NF-kappaB for therapy of lymphomas","volume":"11","author":"Rabson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2006.s.005_bib71","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2004.05239.x","article-title":"Proapoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab","volume":"127","author":"Ramanarayanan","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2006.s.005_bib72","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","article-title":"Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia","volume":"23","author":"O'Brien","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2006.s.005_bib73","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1158\/1078-0432.CCR-05-0308","article-title":"The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide","volume":"12","author":"O'Connor","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2006.s.005_bib74","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2004.11.002","article-title":"Bcl-2 antisense therapy in B-cell malignancies","volume":"19","author":"Chanan-Khan","year":"2005","journal-title":"Blood Rev"},{"key":"10.3816\/CLM.2006.s.005_bib75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.surg.2006.03.014","article-title":"Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer","volume":"140","author":"Masui","year":"2006","journal-title":"Surgery"},{"key":"10.3816\/CLM.2006.s.005_bib76","first-page":"429a","article-title":"The small molecule pan-Bcl-2 inhibitor GX15-070 induces apoptosis in vitro in mantle cell lymphoma (MCL) cells and exhibits a synergistic effect in combination with the proteasome inhibitor bortezomib","volume":"106","author":"Patricia Perez Galan","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2006.s.005_bib77","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","article-title":"Tumoricidal activity of a novel antihuman DR5 monoclonal antibody without hepatocyte cytotoxicity","volume":"7","author":"Ichikawa","year":"2001","journal-title":"Nat Med"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T22:49:23Z","timestamp":1684536563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":77,"alternative-id":["S1557919011703365"],"URL":"https:\/\/doi.org\/10.3816\/clm.2006.s.005","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}